Best Stocks Under $2 Right Now It can be difficult to find a deal in the stock market regardless of current market conditions. For the last decade, stocks have traded well above historical average P/E ratios. Fortunately there are still a handful of undervalued stocks in corners of the market that most investors ignore. This page lists cheap stocks that have a share price of $2.00 (2 dollars) or less and consisently-receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts. OverviewStocks Under $0.05Stocks Under $0.10Stocks Under $0.25Stocks Under $0.50Stocks Under $1Stocks Under $2Stocks Under $3Stocks Under $5Stocks Under $10Stocks Under $20Stocks Under $30Stocks Under $50Stocks On Sale 1. Cardiol Therapeutics NASDAQ:CRDL$1.45 +0.01 (+0.69%) Closing price 06/10/2025 04:00 PM EasternExtended Trading$1.44 -0.01 (-0.69%) As of 06/10/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. More about Cardiol TherapeuticsMarket Capitalization$119.84 millionP/E Ratio-3.72Consensus RatingBuyConsensus Price Target$8.67 (+497.7% Upside)Volume347,819 sharesAverage Volume348,013 shares Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. 2. OS Therapies NYSE:OSTX$1.96 -0.02 (-1.01%) Closing price 06/10/2025 04:00 PM EasternExtended Trading$1.93 -0.03 (-1.58%) As of 06/10/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. More about OS TherapiesMarket Capitalization$55.07 millionP/E Ratio-2.28Consensus RatingBuyConsensus Price Target$18.00 (+818.4% Upside)Volume1.34 million sharesAverage Volume470,109 shares3. Denison Mines NYSEAMERICAN:DNN$1.58 -0.14 (-8.14%) Closing price 06/10/2025 04:10 PM EasternExtended Trading$1.59 +0.01 (+0.57%) As of 06/10/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Denison Mines Corp. engages in the acquisition, exploration, and development of uranium bearing properties in Canada. Its flagship project is the Wheeler River uranium project covering an area of approximately 300,000 hectares located in the Athabasca Basin region in northern Saskatchewan. More about Denison MinesMarket Capitalization$1.42 billionP/E Ratio-158.00Consensus RatingBuyConsensus Price Target$3.00 (+89.9% Upside)Volume194.56 million sharesAverage Volume40.56 million shares4. Reviva Pharmaceuticals NASDAQ:RVPH$0.84 -0.01 (-0.59%) Closing price 06/10/2025 04:00 PM EasternExtended Trading$0.86 +0.02 (+2.74%) As of 06/10/2025 07:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. More about Reviva PharmaceuticalsMarket Capitalization$39.26 millionP/E Ratio-0.76Consensus RatingBuyConsensus Price Target$9.00 (+971.4% Upside)Volume342,904 sharesAverage Volume1.15 million shares5. Quince Therapeutics NASDAQ:QNCX$1.20 +0.03 (+2.56%) Closing price 06/10/2025 04:00 PM EasternExtended Trading$1.19 -0.01 (-0.83%) As of 06/10/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. More about Quince TherapeuticsMarket Capitalization$54.56 millionP/E Ratio-0.97Consensus RatingBuyConsensus Price Target$8.00 (+566.7% Upside)Volume87,587 sharesAverage Volume289,541 shares6. GeoVax Labs NASDAQ:GOVX$1.22 +0.04 (+3.39%) As of 06/10/2025 04:00 PM EasternGeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. More about GeoVax LabsMarket Capitalization$18.54 millionP/E Ratio-0.33Consensus RatingBuyConsensus Price Target$11.10 (+809.8% Upside)Volume642,433 sharesAverage Volume520,459 shares7. Immunic NASDAQ:IMUX$0.89 +0.02 (+2.08%) Closing price 06/10/2025 04:00 PM EasternExtended Trading$0.89 +0.01 (+0.76%) As of 06/10/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. More about ImmunicMarket Capitalization$84.83 millionP/E Ratio-0.72Consensus RatingBuyConsensus Price Target$11.60 (+1,210.3% Upside)Volume1.40 million sharesAverage Volume874,778 shares8. Western Copper & Gold NYSE:WRN$1.26 +0.02 (+1.20%) As of 06/10/2025 04:00 PM EasternWestern Copper & Gold Corp. operates as an exploration stage company, which engages in the acquisition, exploration, and future development of mineral resource properties. More about Western Copper & GoldMarket Capitalization$252.01 millionP/E Ratio-63.00Consensus RatingBuyConsensus Price Target$4.25 (+237.3% Upside)Volume189,314 sharesAverage Volume370,400 shares9. Ur-Energy NYSEAMERICAN:URG$0.95 -0.03 (-3.14%) Closing price 06/10/2025 04:10 PM EasternExtended Trading$0.95 0.00 (-0.48%) As of 06/10/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ur-Energy Inc engages in the acquisition, exploration, development, and operation of uranium mineral properties. The company holds interests in 12 projects located in the United States. More about Ur-EnergyMarket Capitalization$346.11 millionP/E Ratio-7.31Consensus RatingBuyConsensus Price Target$2.30 (+142.0% Upside)Volume8.20 million sharesAverage Volume4.34 million shares10. FibroBiologics NASDAQ:FBLG$0.94 -0.01 (-0.93%) Closing price 06/10/2025 04:00 PM EasternExtended Trading$0.92 -0.02 (-1.71%) As of 06/10/2025 07:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. More about FibroBiologicsMarket Capitalization$35.81 millionP/E Ratio-4.46Consensus RatingBuyConsensus Price Target$13.00 (+1,288.9% Upside)Volume377,765 sharesAverage Volume295,978 shares11. Lucid Diagnostics NASDAQ:LUCD$1.30 0.00 (0.00%) Closing price 06/10/2025 04:00 PM EasternExtended Trading$1.31 +0.01 (+0.85%) As of 06/10/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. More about Lucid DiagnosticsMarket Capitalization$140.65 millionP/E Ratio-1.14Consensus RatingBuyConsensus Price Target$3.55 (+173.1% Upside)Volume1.16 million sharesAverage Volume577,117 shares12. Rani Therapeutics NASDAQ:RANI$0.58 +0.01 (+1.53%) Closing price 06/10/2025 04:00 PM EasternExtended Trading$0.60 +0.02 (+2.59%) As of 06/10/2025 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. More about Rani TherapeuticsMarket Capitalization$33.51 millionP/E Ratio-0.55Consensus RatingBuyConsensus Price Target$9.40 (+1,512.6% Upside)Volume653,149 sharesAverage Volume812,585 shares13. Context Therapeutics NASDAQ:CNTX$0.67 -0.03 (-4.89%) Closing price 06/10/2025 04:00 PM EasternExtended Trading$0.73 +0.07 (+9.80%) As of 06/10/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. More about Context TherapeuticsMarket Capitalization$59.97 millionP/E Ratio-0.73Consensus RatingBuyConsensus Price Target$6.00 (+797.5% Upside)Volume417,317 sharesAverage Volume297,848 shares14. Stardust Power NASDAQ:SDST$0.61 0.00 (-0.05%) Closing price 06/10/2025 04:00 PM EasternExtended Trading$0.60 -0.01 (-2.28%) As of 06/10/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Stardust Power Inc is a vertically-integrated lithium refinery that engages in producing battery-grade lithium. The company was founded in 2022 and is based in Greenwich, Connecticut.Market Capitalization$36.94 millionP/E Ratio-0.83Consensus RatingBuyConsensus Price Target$5.11 (+732.7% Upside)Volume146,170 sharesAverage Volume396,832 shares15. Gain Therapeutics NASDAQ:GANX$1.89 -0.02 (-1.05%) Closing price 06/10/2025 04:00 PM EasternExtended Trading$1.90 +0.02 (+0.79%) As of 06/10/2025 06:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. More about Gain TherapeuticsMarket Capitalization$56.60 millionP/E Ratio-1.72Consensus RatingBuyConsensus Price Target$8.20 (+333.9% Upside)Volume268,766 sharesAverage Volume312,522 shares16. Nkarta NASDAQ:NKTX$1.99 +0.12 (+6.42%) Closing price 06/10/2025 04:00 PM EasternExtended Trading$1.99 0.00 (0.00%) As of 06/10/2025 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. More about NkartaMarket Capitalization$141.21 millionP/E Ratio-1.06Consensus RatingBuyConsensus Price Target$14.33 (+620.3% Upside)Volume828,868 sharesAverage Volume1.06 million shares17. ProQR Therapeutics NASDAQ:PRQR$1.77 -0.06 (-3.28%) Closing price 06/10/2025 04:00 PM EasternExtended Trading$1.84 +0.07 (+3.95%) As of 06/10/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. More about ProQR TherapeuticsMarket Capitalization$186.23 millionP/E Ratio-5.53Consensus RatingBuyConsensus Price Target$8.00 (+352.0% Upside)Volume240,793 sharesAverage Volume638,564 shares18. Zura Bio NASDAQ:ZURA$1.28 +0.03 (+2.40%) Closing price 06/10/2025 04:00 PM EasternExtended Trading$1.30 +0.02 (+1.56%) As of 06/10/2025 06:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. More about Zura BioMarket Capitalization$87.52 millionP/E Ratio-1.83Consensus RatingBuyConsensus Price Target$14.33 (+1,019.8% Upside)Volume908,030 sharesAverage Volume431,587 shares19. Aclaris Therapeutics NASDAQ:ACRS$1.51 +0.02 (+1.34%) Closing price 06/10/2025 04:00 PM EasternExtended Trading$1.50 -0.01 (-0.66%) As of 06/10/2025 06:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. More about Aclaris TherapeuticsMarket Capitalization$163.50 millionP/E Ratio-2.90Consensus RatingBuyConsensus Price Target$9.71 (+543.3% Upside)Volume298,956 sharesAverage Volume1.20 million shares20. Erasca NASDAQ:ERAS$1.61 -0.02 (-1.23%) Closing price 06/10/2025 04:00 PM EasternExtended Trading$1.58 -0.03 (-1.55%) As of 06/10/2025 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Erasca, Inc, a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. More about ErascaMarket Capitalization$456.09 millionP/E Ratio-1.94Consensus RatingBuyConsensus Price Target$4.57 (+183.9% Upside)Volume1.03 million sharesAverage Volume1.75 million shares21. TScan Therapeutics NASDAQ:TCRX$1.69 -0.08 (-4.52%) Closing price 06/10/2025 04:00 PM EasternExtended Trading$1.74 +0.06 (+3.25%) As of 06/10/2025 07:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. More about TScan TherapeuticsMarket Capitalization$95.64 millionP/E Ratio-1.59Consensus RatingBuyConsensus Price Target$7.80 (+361.5% Upside)Volume291,262 sharesAverage Volume412,834 shares22. FiscalNote NYSE:NOTE$0.57 -0.07 (-10.77%) Closing price 06/10/2025 03:59 PM EasternExtended Trading$0.59 +0.02 (+2.61%) As of 06/10/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.FiscalNote Holdings, Inc operates as technology company North America, Europe, Australia, and Asia. It combines artificial intelligence technology, machine learning, and other technologies with analytics, workflow tools, and expert research. More about FiscalNoteMarket Capitalization$90.82 millionP/E Ratio-2.61Consensus RatingBuyConsensus Price Target$2.63 (+358.8% Upside)Volume5.87 million sharesAverage Volume1.66 million shares23. Cresco Labs OTCMKTS:CRLBF$0.52 -0.02 (-4.03%) As of 06/10/2025 03:59 PM EasternCresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. More about Cresco LabsMarket Capitalization$252.87 millionP/E Ratio-2.58Consensus RatingBuyVolume411,471 sharesAverage Volume650,164 sharesToday's Range$0.51▼$0.5624. Lineage Cell Therapeutics NYSEAMERICAN:LCTX$0.75 +0.03 (+3.66%) Closing price 06/10/2025 04:10 PM EasternExtended Trading$0.74 -0.01 (-0.68%) As of 06/10/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. More about Lineage Cell TherapeuticsMarket Capitalization$164.24 millionP/E Ratio-6.21Consensus RatingBuyConsensus Price Target$4.20 (+463.7% Upside)Volume7.37 million sharesAverage Volume1.33 million shares25. Acrivon Therapeutics NASDAQ:ACRV$1.28 0.00 (0.00%) Closing price 06/10/2025 04:00 PM EasternExtended Trading$1.32 +0.04 (+3.13%) As of 06/10/2025 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. More about Acrivon TherapeuticsMarket Capitalization$40.13 millionP/E Ratio-0.47Consensus RatingBuyConsensus Price Target$17.71 (+1,283.9% Upside)Volume353,610 sharesAverage Volume249,984 shares More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CrowdStrike Stock Hits All-Time Highs: Smart Buy or FOMO Trap? These 3 Stocks Could Be Back in Play Before You Know It Casey’s Surges on Strong Q4, More Gains Likely Ahead Qualcomm: What Monday’s Jump Tells Us About the Stock's Prospects Government Mandate Sends eVTOL Stocks Flying AppLovin Dips on S&P 500 Snub, Morgan Stanley Lifts Target Anyway Meta Pulls Ahead of the Mag 7: Analysts Predict a Breakout Year ASML’s AI Edge: How Its EUV Tech Is Creating a New Monopoly Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
